| 11.17 0 (0%) | 12-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Viatris Inc. completed its acquisition of Oyster Point Pharma, Inc. on January 3, 2023. Prior to this, Oyster Point Pharma operated as a commercial-stage biopharmaceutical firm, primarily focused on discovering, developing, and commercializing pharmaceutical treatments for various eye conditions within the United States. The company's principal investigational therapy is TYRVAYA, a nicotinic acetylcholine receptor agonist designed to alleviate the signs and symptoms of dry eye disease. TYRVAYA is also being evaluated in a Phase II clinical trial for its potential application in treating neurotrophic keratopathy. Oyster Point Pharma was founded in 2015 and was headquartered in Princeton, New Jersey.
Tue, 08 Nov 2022
Oyster Point Pharma to Be Acquired by Viatris - VisionMonday.com
Mon, 07 Nov 2022
Viatris (VTRS) Stock Pops 17% on Acquisition News - InvestorPlace
Mon, 07 Nov 2022
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris - GlobeNewswire
Wed, 24 Nov 2021
Oyster Point Pharma Announces Expansion of Executive Leadership Team - citybiz
Mon, 18 Oct 2021
Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Na - MultiVu
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|